|
Factor
|
BSI (n = 92)
|
non-BSI (n = 244)
|
Univariate analysis
|
Multivariate analysis
|
|---|
|
P
|
OR (95% CI)
|
P
|
|---|
|
Gender
| | |
0.634
| | |
|
Male
|
57
|
158
| | | |
|
Female
|
35
|
86
| | | |
|
Age [years]
| | |
0.037
| |
0.164
|
|
<=14
|
53
|
170
| | | |
|
> 14
|
39
|
74
| | | |
|
Disease
| | |
< 0.001
| |
0.007
|
|
AML
|
33
|
77
| | | |
|
ALL
|
34
|
143
| |
0.611(0.343–1.089)
| |
|
CML
|
8
|
8
| |
1.578(0.482–5.168)
| |
|
MDS
|
12
|
10
| |
2.752(1.015–7.464)
| |
|
Others
|
5
|
6
| |
2.870(0.769–10.710)
| |
|
Conditioning regimen
| | |
0.001
|
1.755(1.008–3.057)
|
0.047
|
|
Not including TBI
|
49
|
178
| | | |
|
Including TBI
|
43
|
66
| | | |
|
State of disease
| | |
0.016
| |
0.640
|
|
CR or Chronic phase
|
62
|
195
| | | |
|
NR or Advanced phase
|
30
|
49
| | | |
|
HLA match (low-resolution)
| | |
0.75
| | |
|
4/6
|
33
|
80
| | | |
|
5/6
|
46
|
122
| | | |
|
6/6
|
13
|
42
| | | |
|
Total nucleated-cell dose
| | |
0.035
| |
0.940
|
|
< =4.17 × 107/kg
|
55
|
114
| | | |
|
> 4.17 × 107/kg
|
37
|
129
| | | |
|
Total CD34+ cell dose
| | |
0.079
| |
0.977
|
|
< =2.32 × 105/kg
|
54
|
117
| | | |
|
> 2.32 × 105/kg
|
38
|
127
| | | |
|
Time of neutrophil recovery
| | |
< 0.001
|
1.117(1.056–1.118)
|
0.000
|
|
< =17d
|
34
|
150
| | | |
|
> 17d
|
58
|
94
| | | |
- OR odds ratio, CI confidence interval
